Alliance News
 
Working Together
 
Doing Our Part
 
Deep Resources
Our Pipeline of Developed Compounds
Case Histories

 

 
  » BMS.com Home » Alliances » Doing Our Part » The logical evolution of a relationship.
 
 



 

Case histories
The logical evolution of a relationship.

Pravachol® (pravastatin sodium) tablets

Bristol-Myers Squibb and Sankyo had a more than 40-year history of successfully growing together around the world, behind such cardiovascular products as captopril. So the 1985 agreement to collaborate around Sankyo's cholesterol-lowering drug Pravachol® (pravastatin sodium) was a logical next step.

Sankyo launched the product in Japan in 1989. Bristol-Myers Squibb launched in Europe and the U.S. shortly thereafter. And Pravachol became a global blockbuster, with sales of close to $4 billion per year. We are looking forward to celebrating 50 years of creating and sharing value together.

Full Prescribing Information for Pravachol®


[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Atripla is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

 
SEARCH INDEX